Transcranial Magnetic Stimulation to Improve Functioning in Veterans With PTSD (rTMS for PTSD)
Primary Purpose
PTSD
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
TMS 1 hz
Sham TMS
Sponsored by

About this trial
This is an interventional treatment trial for PTSD focused on measuring Transcranial Magnetic Stimulation, Stress Disorders, Post-Traumatic
Eligibility Criteria
Inclusion Criteria:
- Age between 19 and 70
- Moderate to severe PTSD as determined by the CAPS within 7 days of randomization.
- Agree to have CAPS audio-recorded.
- Ability to obtain a Motor Threshold using the TMS device during screening.
- Patient eligible for VA healthcare.
- If female with childbearing potential, use of acceptable method of birth control (i.e., use of contraceptives, abstinence).
- Able to read, understand, and sign the informed consent document.
Exclusion Criteria:
- Pregnant or lactating woman.
- Current use of clozapine (any dose) or bupropion (more than 300mg per day).
- Cardiac pacemaker or implantable defibrillator.
- Presence of any metal object in the head, including cochlear implants, but excluding dental work in the mouth.
- Significant central nervous system disorder (stroke, brain mass, epilepsy).
- Seizure in past one year.
- Current psychosis or mania.
- Prior use of TMS.
- Significant suicidal ideation.
- Unstable medical conditions.
- Current alcohol or substance use disorder (except nicotine) that interferes with the patient's ability to participate.
- CPT or PE for PTSD in the past 2 months.
- Changes in Fluoxetine, Paroxetine, Sertraline, or Venlafaxine in the past 2 months.
Sites / Locations
- White River Junction VA Medical Center, White River Junction, VTRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
TMS
Sham
Arm Description
transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex at 1 Hz
sham transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex
Outcomes
Primary Outcome Measures
CAPS
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD. The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
WHODAS
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society. The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials. The total score ranges from 0-100 with a higher score indicating worse functioning.
QIDS SR-16
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression. The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV. The score ranges from 0-27 with a higher score indicating worse depression.
CAPS
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD. The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
CAPS
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD. The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
CAPS
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD. The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
WHODAS
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society. The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials. The total score ranges from 0-100 with a higher score indicating worse functioning.
WHODAS
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society. The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials. The total score ranges from 0-100 with a higher score indicating worse functioning.
WHODAS
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society. The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials. The total score ranges from 0-100 with a higher score indicating worse functioning.
QIDS SR-16
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression. The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV. The score ranges from 0-27 with a higher score indicating worse depression.
QIDS SR-16
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression. The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV. The score ranges from 0-27 with a higher score indicating worse depression.
QIDS SR-16
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression. The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV. The score ranges from 0-27 with a higher score indicating worse depression.
Secondary Outcome Measures
Full Information
NCT ID
NCT04207346
First Posted
December 18, 2019
Last Updated
March 14, 2023
Sponsor
VA Office of Research and Development
1. Study Identification
Unique Protocol Identification Number
NCT04207346
Brief Title
Transcranial Magnetic Stimulation to Improve Functioning in Veterans With PTSD
Acronym
rTMS for PTSD
Official Title
Transcranial Magnetic Stimulation to Improve Functioning in Veterans With PTSD
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Posttraumatic Stress Disorder (PTSD) is a common and serious condition affecting many Veterans. There are effective treatments for PTSD, but additional treatments are needed in order to better serve Veterans suffering from PTSD. Transcranial magnetic stimulation is one such promising treatment. It involves use of powerful magnet to stimulate the specific brain regions in Veterans with PTSD. Transcranial magnetic stimulation has been shown effective in treating depression, but currently it is unclear if it is an effective treatment for PTSD. This is a randomized clinical trial enrolling 91 Veterans with PTSD comparing the effectiveness of transcranial magnetic stimulation treatment and sham transcranial magnetic stimulation in treating PTSD. The hypothesis is that those who receive transcranial magnetic stimulation will experience improved functioning.
Detailed Description
Background Posttraumatic Stress Disorder (PTSD) is an often chronic and disabling condition prevalent in the Veteran population. While there is sufficient evidence to demonstrate the effectiveness of medications and psychotherapy for improving PTSD symptoms, there has been limited study of functioning as an outcome, and the role of other treatments such as somatic therapies. One promising but understudied somatic treatment for PTSD is repetitive transcranial magnetic stimulation (TMS). The characteristics of TMS treatment are different than those of existing treatments and may provide alternative treatment to Veterans who do not respond to medications and psychotherapy. Further, it is possible that TMS may have a greater effect on functioning and lead to higher rates of recovery compared with medications or psychotherapy.
Objective To determine whether Veteran participants with PTSD who receive TMS delivered to the right dorsolateral prefrontal cortex at 1 Hz have greater improvements in: PTSD symptoms, functioning, and depressive symptoms than Veterans receiving sham treatments at treatment completion and at 3 and 6 months after treatment completion.
Method 91 Veterans with PTSD will be randomly assigned to receive low frequency TMS or sham TMS. All TMS will be applied to the right dorsolateral prefrontal cortex. PTSD symptoms, functional outcomes, and depressive symptoms will be measured for all participants at treatment completion, 3 months, and 6 months after completion.
Hypothesis Veterans with PTSD receiving TMS will have greater improvements in PTSD symptoms, functioning, and depressive symptoms at treatment completion and at three and six months after treatment completion compared to Veterans receiving sham TMS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PTSD
Keywords
Transcranial Magnetic Stimulation, Stress Disorders, Post-Traumatic
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are assigned to one of two or more groups in parallel for the duration of the study: procedure vs. sham procedure
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
91 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TMS
Arm Type
Experimental
Arm Description
transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex at 1 Hz
Arm Title
Sham
Arm Type
Sham Comparator
Arm Description
sham transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex
Intervention Type
Device
Intervention Name(s)
TMS 1 hz
Other Intervention Name(s)
MagPro R30 TMS device produced by MagVenture
Intervention Description
High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the active side.
Intervention Type
Device
Intervention Name(s)
Sham TMS
Other Intervention Name(s)
MagPro R30 TMS device produced by MagVenture
Intervention Description
High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the sham side.
Primary Outcome Measure Information:
Title
CAPS
Description
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD. The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
Time Frame
Baseline
Title
WHODAS
Description
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society. The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials. The total score ranges from 0-100 with a higher score indicating worse functioning.
Time Frame
Baseline
Title
QIDS SR-16
Description
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression. The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV. The score ranges from 0-27 with a higher score indicating worse depression.
Time Frame
Baseline
Title
CAPS
Description
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD. The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
Time Frame
2 weeks
Title
CAPS
Description
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD. The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
Time Frame
3 months
Title
CAPS
Description
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD. The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
Time Frame
6 months
Title
WHODAS
Description
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society. The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials. The total score ranges from 0-100 with a higher score indicating worse functioning.
Time Frame
2 weeks
Title
WHODAS
Description
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society. The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials. The total score ranges from 0-100 with a higher score indicating worse functioning.
Time Frame
3 months
Title
WHODAS
Description
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society. The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials. The total score ranges from 0-100 with a higher score indicating worse functioning.
Time Frame
6 months
Title
QIDS SR-16
Description
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression. The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV. The score ranges from 0-27 with a higher score indicating worse depression.
Time Frame
2 weeks
Title
QIDS SR-16
Description
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression. The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV. The score ranges from 0-27 with a higher score indicating worse depression.
Time Frame
3 months
Title
QIDS SR-16
Description
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression. The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV. The score ranges from 0-27 with a higher score indicating worse depression.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age between 19 and 70
Moderate to severe PTSD as determined by the CAPS within 7 days of randomization.
Agree to have CAPS audio-recorded.
Ability to obtain a Motor Threshold using the TMS device during screening.
Patient eligible for VA healthcare.
If female with childbearing potential, use of acceptable method of birth control (i.e., use of contraceptives, abstinence).
Able to read, understand, and sign the informed consent document.
Exclusion Criteria:
Pregnant or lactating woman.
Current use of clozapine (any dose) or bupropion (more than 300mg per day).
Cardiac pacemaker or implantable defibrillator.
Presence of any metal object in the head, including cochlear implants, but excluding dental work in the mouth.
Significant central nervous system disorder (stroke, brain mass, epilepsy).
Seizure in past one year.
Current psychosis or mania.
Prior use of TMS.
Significant suicidal ideation.
Unstable medical conditions.
Current alcohol or substance use disorder (except nicotine) that interferes with the patient's ability to participate.
CPT or PE for PTSD in the past 2 months.
Changes in Fluoxetine, Paroxetine, Sertraline, or Venlafaxine in the past 2 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bradley V Watts, MD MPH
Phone
(802) 295-9363
Ext
5235
Email
Bradley.Watts@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bradley V Watts, MD MPH
Organizational Affiliation
White River Junction VA Medical Center, White River Junction, VT
Official's Role
Principal Investigator
Facility Information:
Facility Name
White River Junction VA Medical Center, White River Junction, VT
City
White River Junction
State/Province
Vermont
ZIP/Postal Code
05001-3833
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diane L Rivera
Phone
802-295-9363
Ext
5373
Email
Diana.rivera@va.gov
First Name & Middle Initial & Last Name & Degree
Cory E Gaudette, AA
Phone
(802) 295-9363
Ext
6880
Email
cory.gaudette@va.gov
First Name & Middle Initial & Last Name & Degree
Bradley V Watts, MD MPH
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Transcranial Magnetic Stimulation to Improve Functioning in Veterans With PTSD
We'll reach out to this number within 24 hrs